» Articles » PMID: 7660122

Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein

Overview
Journal Science
Specialty Science
Date 1995 Sep 8
PMID 7660122
Citations 158
Authors
Affiliations
Soon will be listed here.
Abstract

Germline mutations in the von Hippel-Lindau tumor suppressor gene (VHL) predispose individuals to a variety of tumors, including renal carcinoma, hemangioblastoma of the central nervous system, and pheochromocytoma. Here, a cellular transcription factor, Elongin (SIII), is identified as a functional target of the VHL protein. Elongin (SIII) is a heterotrimer consisting of a transcriptionally active subunit (A) and two regulatory subunits (B and C) that activate transcription elongation by RNA polymerase II. The VHL protein was shown to bind tightly and specifically to the Elongin B and C subunits and to inhibit Elongin (SIII) transcriptional activity in vitro. These findings reveal a potentially important transcriptional regulatory network in which the VHL protein may play a key role.

Citing Articles

Stepwise order in protein complex assembly: approaches and emerging themes.

Brown M, McMurray M Open Biol. 2025; 15(1):240283.

PMID: 39809320 PMC: 11732423. DOI: 10.1098/rsob.240283.


Penfluridol inhibits melanoma growth and metastasis through enhancing von Hippel‒Lindau tumor suppressor-mediated cancerous inhibitor of protein phosphatase 2A (CIP2A) degradation.

Xu F, Li J, Ai M, Zhang T, Ming Y, Li C MedComm (2020). 2024; 5(10):e758.

PMID: 39399646 PMC: 11470999. DOI: 10.1002/mco2.758.


Total loss of gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity.

Abu-Remaileh M, Persky N, Lee Y, Root D, Kaelin Jr W Proc Natl Acad Sci U S A. 2024; 121(40):e2410356121.

PMID: 39320914 PMC: 11459182. DOI: 10.1073/pnas.2410356121.


Biological hypoxia in pre-transplant human pancreatic islets induces transplant failure in diabetic mice.

Kato H, Salgado M, Mendez D, Gonzalez N, Rawson J, Ligot D Sci Rep. 2024; 14(1):12402.

PMID: 38811610 PMC: 11137081. DOI: 10.1038/s41598-024-61604-3.


Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.

Curry L, Soleimani M Future Oncol. 2024; 20(18):1251-1266.

PMID: 38639572 PMC: 11318713. DOI: 10.2217/fon-2023-0679.